Summary & Overview
CPT 0063U: NPDX ASD ADM Panel I, 32-Amino Acid Biomarker Panel with Algorithm
CPT code 0063U designates a proprietary laboratory test — the NPDX ASD ADM Panel I from Stemina Biomarker Discovery, Inc. — that quantifies 32 amines and applies an algorithmic analysis to detect metabolic signatures associated with autism spectrum disorder (ASD). Nationally, the introduction of PLA codes like 0063U matters because they document use of single-manufacturer assays and enable distinct billing and tracking for novel diagnostics that combine laboratory measurement with proprietary algorithms.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The coverage landscape for PLA assays often varies by payer and hinges on clinical validation, algorithm transparency, and demonstrated impact on patient management.
Readers will learn the clinical scope of the test, expected service setting, and how 0063U fits into payer coverage discussions. The publication provides benchmarks for how PLA codes are handled by major payers, summarizes relevant policy considerations affecting algorithm-based diagnostics, and outlines the clinical context for using an ASD-focused metabolic panel. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0063U is a Proprietary Laboratory Analyses (PLA) code for the NPDX ASD ADM Panel I test developed by Stemina Biomarker Discovery, Inc. The test measures a panel of 32 amines and uses an algorithmic analysis of those results to identify metabolic byproduct patterns consistent with an autism spectrum disorder (ASD) diagnosis.
Service type: Laboratory — proprietary biomarker panel with algorithmic interpretation
Typical site of service: Independent clinical laboratory or reference laboratory
Clinical & Coding Specifications
Clinical Context
A pediatric patient aged 18–48 months presents to a developmental pediatrics clinic for evaluation of delayed social communication, repetitive behaviors, and language regression. The clinician documents concern for autism spectrum disorder (ASD) after standardized screening (for example, M-CHAT) and developmental testing. As part of the diagnostic workup, the clinician orders the proprietary laboratory test 0063U (NPDX ASD ADM Panel I from Stemina Biomarker Discovery, Inc.) to assess a metabolic amine profile and algorithmic pattern consistent with ASD. Blood or plasma is collected in the outpatient clinic or affiliated phlebotomy lab; the specimen is sent to the performing laboratory under chain-of-custody and required transport conditions. The laboratory performs quantitative analysis of 32 amines and runs the manufacturer’s proprietary algorithm to generate a report indicating whether the metabolic pattern is consistent with ASD. Results are returned to the ordering clinician, who integrates the laboratory findings with clinical history, behavioral assessments, and developmental testing to inform diagnosis and care planning. Typical sites of service include outpatient physician offices, specialty developmental pediatrics clinics, hospital outpatient laboratories, and the performing reference laboratory. Technical billing for the test is submitted using PLA code 0063U with appropriate specimen and facility modifiers as needed; professional interpretation may be billed if the reporting laboratory or ordering clinician meets payer rules for reporting the professional component.
Coding Specifications
| Modifier | Description | When to Use |
|---|